• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环游离 DNA 在卵巢癌患者中的潜在临床应用。

Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.

机构信息

Cancer Genetics Group,IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto),Porto,Portugal.

Department of Genetics,Portuguese Oncology Institute of Porto (IPO-Porto),Porto,Portugal.

出版信息

Expert Rev Mol Med. 2018 Dec 18;20:e6. doi: 10.1017/erm.2018.5.

DOI:10.1017/erm.2018.5
PMID:30558693
Abstract

Circulating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called 'liquid biopsy', as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.

摘要

循环游离 DNA(cfDNA)由在血液中自由循环的小 DNA 片段组成。在癌症患者中,cfDNA 的一部分来源于肿瘤细胞,因此含有相同的遗传和表观遗传改变,被称为循环游离肿瘤 DNA。cfDNA(所谓的“液体活检”)作为一种非侵入性癌症生物标志物的潜在用途最近受到了广泛关注。本综述将重点关注 cfDNA 在卵巢癌患者中的潜在临床应用的研究。

相似文献

1
Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.循环游离 DNA 在卵巢癌患者中的潜在临床应用。
Expert Rev Mol Med. 2018 Dec 18;20:e6. doi: 10.1017/erm.2018.5.
2
Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.游离 DNA 大量存在于腹水中,代表了卵巢癌的液体活检。
Gynecol Oncol. 2021 Sep;162(3):720-727. doi: 10.1016/j.ygyno.2021.06.028. Epub 2021 Jul 5.
3
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?液体活检在卵巢癌中应用循环肿瘤 DNA 和细胞:是否已经准备好进入黄金时代?
Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11.
4
Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.无细胞游离 DNA 作为结直肠癌的一种基于血液的诊断生物标志物:系统评价。
J Surg Res. 2019 Apr;236:184-197. doi: 10.1016/j.jss.2018.11.029. Epub 2018 Dec 21.
5
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.无细胞游离 DNA 在转移性结直肠癌中的应用:系统评价和荟萃分析。
Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4.
6
Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.液体活检中的循环肿瘤 DNA:当前的诊断局限性。
World J Gastroenterol. 2024 Apr 21;30(15):2175-2178. doi: 10.3748/wjg.v30.i15.2175.
7
Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.循环游离 DNA 完整性和浓度作为转移性乳腺癌的独立预后标志物。
Breast Cancer Res Treat. 2018 May;169(1):69-82. doi: 10.1007/s10549-018-4666-5. Epub 2018 Jan 16.
8
Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.血浆 DNA 的完整性与卵巢癌患者疫苗诱导的抗肿瘤免疫呈负相关。
Cancer Immunol Immunother. 2020 Oct;69(10):2001-2007. doi: 10.1007/s00262-020-02599-4. Epub 2020 May 11.
9
5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.循环无细胞 DNA 中的 5-羟甲基胞嘧啶特征作为人类癌症的诊断生物标志物。
Cell Res. 2017 Oct;27(10):1243-1257. doi: 10.1038/cr.2017.121. Epub 2017 Sep 19.
10
Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.循环无细胞 DNA 和循环肿瘤细胞,卵巢癌的“液体活检”。
J Ovarian Res. 2017 Nov 13;10(1):75. doi: 10.1186/s13048-017-0369-5.

引用本文的文献

1
Advances and challenges in the use of liquid biopsy in gynaecological oncology.液体活检在妇科肿瘤学中的应用进展与挑战
Heliyon. 2024 Oct 15;10(20):e39148. doi: 10.1016/j.heliyon.2024.e39148. eCollection 2024 Oct 30.
2
Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer.下一代测序技术在卵巢癌血浆循环肿瘤DNA中的当前应用与挑战
Biology (Basel). 2024 Jan 31;13(2):88. doi: 10.3390/biology13020088.
3
Molecular Management of High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌的分子管理
Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.
4
Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer.卵巢癌中循环肿瘤DNA及配对腹水与肿瘤组织的突变分析
Exp Ther Med. 2022 Jun 30;24(3):542. doi: 10.3892/etm.2022.11479. eCollection 2022 Sep.
5
Potential clinical utility of liquid biopsies in ovarian cancer.液体活检在卵巢癌中的潜在临床应用。
Mol Cancer. 2022 May 11;21(1):114. doi: 10.1186/s12943-022-01588-8.
6
Prognostic Significance of Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer.晚期高级别浆液性卵巢癌患者血浆游离DNA甲基化的预后意义
Cancers (Basel). 2021 Dec 21;14(1):4. doi: 10.3390/cancers14010004.
7
Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.肿瘤及配对血浆样本的新一代测序:卵巢癌患者循环肿瘤DNA中体细胞变异的鉴定
Front Oncol. 2021 Sep 30;11:754094. doi: 10.3389/fonc.2021.754094. eCollection 2021.
8
Future Screening Prospects for Ovarian Cancer.卵巢癌的未来筛查前景
Cancers (Basel). 2021 Jul 30;13(15):3840. doi: 10.3390/cancers13153840.
9
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.欧洲妇科肿瘤学会(ESGO)/国际妇产科超声学会(ISUOG)/国际妇产科联盟肿瘤学组(IOTA)/欧洲妇科内镜学会(ESGE)关于卵巢肿瘤术前诊断的共识声明。
Int J Gynecol Cancer. 2021 Jul;31(7):961-982. doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10.
10
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours.ESGO/ISUOG/IOTA/ESGE关于卵巢肿瘤术前诊断的共识声明。
Facts Views Vis Obgyn. 2021 Jun;13(2):107-130. doi: 10.52054/FVVO.13.2.016. Epub 2021 Jun 10.